Mature Results of a Phase III Randomized Trial of Bacillus Calmette-Guerin (BCG) versus Observation and BCG plus Dacarbazine versus BCG in the Adjuvant Therapy of American Joint Committee on Cancer Stage I-III Melanoma (E1673): A Trial of the Eastern Cooperative Oncology Group

Cancer

Volumn 100, Issue 8, 2004, Pages 1692-1698

  Agarwala, Sanjiv S ^a   Neuberg, Donna ^b   Park, Yuhyun ^b   Kirkwood, John M ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Adjuvant therapy; Bacillus Calmette Guerin (BCG); Melanoma; Phase III clinical trials

Indexed keywords

BCG VACCINE; DACARBAZINE;

ABSCESS; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG TOXICITY; HUMAN; INFECTION; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MELANOMA; MUCOSA; MUCOUS MEMBRANE ABNORMALITY; OBSERVATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PUNCTATE ABSCESS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN ABNORMALITY; SKIN MANIFESTATION; SURVIVAL RATE; SURVIVAL TIME; SYSTEMIC DISEASE; SYSTEMIC REACTION; VOMITING;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BCG VACCINE; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 1842582038     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20166     Document Type: Article

References (16)

1. Morton DL, Malmgren RA, Holmes EC, et al. Demonstration of antibodies against human malignant melanoma by immunofluorescence. Surgery. 1968;64:233-240.
2. Gutterman JU, McBride C, Freireich EJ, et al. Active immunotherapy with BCG for recurrent malignant melanoma. Lancet. 1973;1:1208-1212.
3. Morton DL, Eilber FR, Holmes EC, et al. BCG immunotherapy of malignant melanoma: summary of a seven-year experience. Ann Surg. 1974;180;635-643.
4. Sterchi JM, Wells HB, Case LD, et al. A randomized trial of adjuvant chemotherapy and immunotherapy in stage I and stage II cutaneous melanoma: an interim report. Cancer. 1985;55:707-712.
5. Fisher RI, Terry WD, Hodes RJ, et al. Adjuvant immunotherapy or chemotherapy for malignant melanoma: preliminary report of the National Cancer Institute randomized clinical trial. Surg Clin North Am. 1981;61:1267-1277.
6. Veronesi U, Adamus J, Aubert C, et al. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med. 1982;307:913-916.
7. Wood WC, Cosimi AB, Carey RW, et al. Randomized trial of adjuvant therapy for "high-risk" primary malignant melanoma. Surgery. 1978;83:677-681.
8. Ariyan S, Kirkwood JM, Mitchell MS, et al. Intralymphatic and regional surgical adjuvant immunotherapy in high-risk melanoma of the extremities. Surgery. 1982;92:459-463.
9. Kaplan EL, Meier P. Nonparametric estimation of incomplete observations. J Am Stat Assoc. 1958;53:457-481.
10. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B. 1972;74:187-220.
11. Goldie JH. Scientific basis for adjuvant and primary (neoadjuvant) chemotherapy. Semin Oncol. 1987;14:1-7.
12. Weiss DW. MER and other mycobacterial fractions in the immunotherapy of cancer. Med Clin North Am. 1976;60: 473-497.
13. Barth A, Morton DL. The role of adjuvant therapy in melanoma management. Cancer. 1995;75:726-734.
14. Cascinelli N, Rümke P, MacKie R, et al. The significance of conversion of skin reactivity to efficacy of bacillus Calmette-Guerin (BCG) vaccinations given immediately after radical surgery in stage II melanoma patients. Cancer Immunol Immunother. 1989;28:282-286.
15. Agarwala S, Kirkwood J. Interferons and adjuvant therapy. In: Balch CM, Blackwell PM, Houghton AN, editors. Cutaneous melanoma, 4th edition. St. Louis: Quality Medical Publishing, Inc., 2003;605-622.
16. Lejeune FJ, Macher E, Kleeberg U, et al. An assessment of DTIC versus levamisole or placebo in the treatment of high risk stage I patients after surgical removal of a primary melanoma of the skin. A phase II adjuvant study (EORTC protocol 18761). Eur J Cancer. 1988;24:S81-S90.